You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 21, 2025

Hoffmann-la Roche Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Hoffmann-la Roche
International Patents:122
US Patents:5
Tradenames:2
Ingredients:2
NDAs:2
Patent Litigation for Hoffmann-la Roche: See patent lawsuits for Hoffmann-la Roche

Drugs and US Patents for Hoffmann-la Roche

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Hoffmann-la Roche INVIRASE saquinavir mesylate TABLET;ORAL 021785-001 Dec 17, 2004 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes 9,365,514 ⤷  Try for Free Y ⤷  Try for Free
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes 11,433,076 ⤷  Try for Free Y ⤷  Try for Free
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes 9,126,931 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Hoffmann-la Roche Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2441753 CA 2017 00024 Denmark ⤷  Try for Free PRODUCT NAME: ALECTINIB, ELLER SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/16/1169/01 20170220
2441753 PA2017017 Lithuania ⤷  Try for Free PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
2441753 C02441753/01 Switzerland ⤷  Try for Free PRODUCT NAME: ALECTINIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65970 26.01.2017
2441753 PA2017017,C2441753 Lithuania ⤷  Try for Free PRODUCT NAME: ALEKTINIBAS ARBA JO DRUSKA, ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/16/1169 20170216
2441753 C20170023 00233 Estonia ⤷  Try for Free PRODUCT NAME: ALEKTINIIB;REG NO/DATE: EU/1/16/1169 20.02.2017
2441753 31/2017 Austria ⤷  Try for Free PRODUCT NAME: ALECTINIB ODER DESSEN SALZE ODER DESSEN SOLVATE; REGISTRATION NO/DATE: EU/1/16/1169 20170220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Hoffmann-la Roche – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Hoffmann-La Roche stands as a formidable player, consistently pushing the boundaries of innovation and maintaining a strong market presence. Let's dive into a comprehensive analysis of Roche's position in the competitive landscape, exploring its strengths, strategic initiatives, and the factors that contribute to its continued success.

Roche's Market Position

Hoffmann-La Roche, commonly known as Roche, has established itself as a global leader in the pharmaceutical and diagnostics sectors. As of 2018, the company held a significant 4.69% market share in the pharmaceutical industry[1]. This impressive standing is a testament to Roche's commitment to innovation and its ability to deliver cutting-edge healthcare solutions.

Global Presence and Revenue

Roche's influence extends far beyond its Swiss roots. The company operates worldwide through two main divisions: Pharmaceuticals and Diagnostics[2]. In 2018, Roche reported revenues of CHF56.84bn ($57.73bn), with the pharmaceutical division contributing the lion's share at CHF44bn ($44.68bn)[1]. This financial performance underscores Roche's robust market position and its ability to generate substantial revenue across diverse markets.

Ranking Among Pharmaceutical Giants

Roche's standing in the industry is further solidified by its ranking as the fifth-largest pharmaceutical company globally by revenue[2]. This achievement is particularly noteworthy given the intense competition in the sector and the rapid pace of technological advancements.

Roche's Key Strengths

Research and Development Powerhouse

One of Roche's most significant strengths lies in its unwavering commitment to research and development (R&D). The company is recognized as the world's largest spender in pharmaceutical R&D[2]. This substantial investment in innovation has allowed Roche to maintain a robust pipeline of potential breakthrough treatments and stay at the forefront of medical advancements.

"Roche has from the very beginning produced innovations that mark milestones in the history of medicine."[3]

Oncology Leadership

Roche has established itself as the leading provider of cancer treatments globally[2]. This specialization in oncology has not only contributed significantly to the company's revenue but has also positioned Roche as a crucial player in the fight against cancer, one of the world's most pressing health challenges.

Integrated Diagnostics and Pharmaceuticals

Roche's unique strength lies in its ability to combine diagnostics and pharmaceuticals within a single company. This integration allows for close coordination between these two critical healthcare sectors, enabling Roche to pioneer personalized healthcare solutions[3]. The synergy between these divisions gives Roche a competitive edge in developing targeted therapies and diagnostic tools.

Strategic Initiatives and Growth Drivers

Focus on Personalized Medicine

Roche has set an ambitious goal of making personalized medicine widely available to patients. The launch of the FoundationOne program exemplifies this commitment, offering patients the option of personalized therapy based on gene sequencing[3]. This strategic focus on tailored healthcare solutions positions Roche at the forefront of a rapidly growing and potentially transformative sector of the pharmaceutical industry.

Continuous Innovation in Diagnostics

The Roche Diagnostics Division is a global leader in in-vitro diagnostics (IVD)[3]. By continuously innovating in this space, Roche is enhancing the speed, accuracy, and reliability of laboratory testing. This focus on diagnostic excellence not only contributes to Roche's revenue but also plays a crucial role in improving overall healthcare outcomes.

Strategic Partnerships and Acquisitions

Roche has strategically expanded its capabilities through key acquisitions and partnerships. The company owns the American biotechnology company Genentech and has a significant stake in the Japanese biotechnology company Chugai Pharmaceuticals[2]. These strategic moves have broadened Roche's research capabilities and market reach.

Product Portfolio and Pipeline

Diverse Therapeutic Areas

Roche's product portfolio spans a wide range of therapeutic areas, including oncology, immunology, neuroscience, ophthalmology, and infectious diseases[4]. This diversification helps mitigate risks associated with over-reliance on a single therapeutic area and allows Roche to address multiple unmet medical needs.

Blockbuster Drugs

Several of Roche's products have achieved blockbuster status, contributing significantly to the company's revenue. Key growth drivers include:

  • Vabysmo (eye disease treatment)
  • Ocrevus (multiple sclerosis)
  • Hemlibra (haemophilia A)
  • Polivy (blood cancer)[6]

Robust Pipeline

Roche's pipeline is a testament to its R&D prowess. Recent highlights include:

  • US approval of Vabysmo for retinal vein occlusion
  • US priority review of Xolair for food allergies
  • EU approval of a subcutaneous form of Tecentriq for cancer immunotherapy
  • Positive phase III data for inavolisib (breast cancer), Xolair (food allergies), and Hemlibra (severe haemophilia A in babies)[6]

Digital Transformation and Technological Innovation

Embracing Emerging Technologies

Roche is actively leveraging emerging technologies to enhance its operational and service capabilities. The company focuses on artificial intelligence, Internet of Things (IoT), cloud-based applications, big data, and precision medicine[4]. This technological focus ensures that Roche remains at the cutting edge of pharmaceutical innovation.

AI-Powered Solutions

In 2024, Roche launched Accu-Chek SmartGuide, a continuous glucose monitoring system that incorporates AI-powered predictions. This system can alert users of potential blood sugar fluctuations 30 minutes to two hours in advance, showcasing Roche's commitment to leveraging technology for improved patient care[4].

Market Challenges and Competition

Intense Industry Competition

Despite its strong market position, Roche faces stiff competition from other pharmaceutical giants such as Novartis, Johnson & Johnson, Merck, and Pfizer[5]. This competitive landscape necessitates continuous innovation and strategic positioning to maintain market share.

Patent Expirations and Biosimilars

Like many pharmaceutical companies, Roche faces challenges related to patent expirations and the entry of biosimilars into the market. For instance, in Japan, the company has had to contend with the impact of biosimilars on its sales[6].

Regulatory Scrutiny

Increasing regulatory scrutiny poses a potential threat to Roche's operations. Navigating complex regulatory environments across different markets requires significant resources and strategic planning[5].

Future Outlook and Growth Opportunities

Expanding Personalized Medicine

The growing demand for personalized medicine presents a significant opportunity for Roche. With its integrated diagnostics and pharmaceuticals approach, the company is well-positioned to lead in this evolving field[3].

Emerging Markets

Roche has shown strong growth in emerging markets, particularly in the International region, led by countries like China, Brazil, and Canada[6]. Continued focus on these markets could drive future growth.

Technological Advancements

Ongoing investments in digital technologies and AI-powered solutions are likely to enhance Roche's competitive edge and open up new avenues for growth and innovation[4].

Key Takeaways

  • Roche holds a strong market position as the fifth-largest pharmaceutical company globally, with a 4.69% market share.
  • The company's key strengths include its substantial R&D investments, leadership in oncology, and integrated diagnostics and pharmaceuticals approach.
  • Roche's focus on personalized medicine and continuous innovation in diagnostics are driving its strategic growth.
  • The company's diverse product portfolio and robust pipeline, spanning multiple therapeutic areas, contribute to its market resilience.
  • Roche is actively embracing digital transformation and leveraging emerging technologies to enhance its operations and product offerings.
  • Despite facing challenges such as intense competition and regulatory scrutiny, Roche's strategic initiatives and focus on innovation position it well for future growth.

FAQs

  1. What is Roche's market share in the pharmaceutical industry? As of 2018, Roche held a 4.69% market share in the pharmaceutical industry.

  2. What are Roche's main business divisions? Roche operates through two main divisions: Pharmaceuticals and Diagnostics.

  3. How does Roche rank among global pharmaceutical companies? Roche is ranked as the fifth-largest pharmaceutical company in the world by revenue.

  4. What is Roche's approach to personalized medicine? Roche aims to make personalized medicine widely available through initiatives like the FoundationOne program, which offers personalized therapy based on gene sequencing.

  5. How is Roche leveraging artificial intelligence in its products? Roche has incorporated AI into products like the Accu-Chek SmartGuide, a glucose monitoring system that uses AI-powered predictions to alert users of potential blood sugar fluctuations.

Sources cited: [1] https://www.pharmaceutical-technology.com/features/top-pharmaceutical-companies/ [2] https://en.wikipedia.org/wiki/Roche [3] https://www.cascade.app/studies/roche-strategy-study [4] https://www.globaldata.com/store/report/f-hoffmann-la-roche-ltd-enterprise-tech-analysis/ [5] https://pitchgrade.com/companies/roche [6] https://assets.roche.com/f/176343/x/5a5b5d48d1/240201_ir_fy23_en.pdf

Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.